Generation of a human induced pluripotent stem cell line derived from a Parkinson's disease patient carrying SNCA duplication

Hidefumi Suzuki; Naohiro Egawa; Takayuki Kondo; Keiko Imamura; Takako Enami; Kayoko Tsukita; Mika Suga; Ran Shibukawa; Yasue Okanishi; Tsuyoshi Uchiyama; Haruhisa Inoue; Ryosuke Takahashi

Stem Cell Research (May 2020)

Generation of a human induced pluripotent stem cell line derived from a Parkinson's disease patient carrying SNCA duplication

Hidefumi Suzuki,
Naohiro Egawa,
Takayuki Kondo,
Keiko Imamura,
Takako Enami,
Kayoko Tsukita,
Mika Suga,
Ran Shibukawa,
Yasue Okanishi,
Tsuyoshi Uchiyama,
Haruhisa Inoue,
Ryosuke Takahashi

Affiliations

Hidefumi Suzuki: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Naohiro Egawa: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
Takayuki Kondo: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan
Keiko Imamura: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan
Takako Enami: Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan
Kayoko Tsukita: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
Mika Suga: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
Ran Shibukawa: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan
Yasue Okanishi: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan
Tsuyoshi Uchiyama: Department of Neurology, Seirei Hamamatsu General Hospital, Shizuoka, Japan
Haruhisa Inoue: iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan; Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan; Medical-risk Avoidance based on iPS Cells Team, RIKEN Center for Advanced Intelligence Project (AIP), Kyoto, Japan; Corresponding authors.
Ryosuke Takahashi: Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan; Corresponding authors.

Journal volume & issue: Vol. 45

Abstract

Read online

Parkinson's disease (PD) is a devastating movement disorder with an unknown etiology. Multiplications of the SNCA gene cause the autosomal dominant form of familial PD as well as missense mutations of the gene. We established and characterized a human induced pluripotent stem cell (iPSC) line from a PD patient carrying SNCA duplication. The iPSC line displayed a capacity to differentiate into midbrain dopaminergic neurons affected in PD. The iPSC line will be useful for disease modeling applications.

Published in Stem Cell Research

ISSN: 1873-5061 (Print); 1876-7753 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Science: Biology (General)
Website: https://www.journals.elsevier.com/stem-cell-research

About the journal